Results 81 to 90 of about 41,377 (182)

Medications That Regulate Pregnane X Receptor: A Systematic Review of Current Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
PRISMA 2020 flow diagram of study selection for this systematic review of medications that regulate the pregnane X receptor (PXR), from 12 236 records screened to 101 included studies. ABSTRACT The pregnane X receptor (PXR) gene encodes a ligand‐activated protein involved with the metabolism and excretion of drugs, toxins, and other xenobiotics.
Petra Czarniak, Rachael Moorin, Jeff Hughes, Karl Gruber, David Youens   +4 more
wiley   +1 more source

From prediction to intervention: Paradigm shifts in causal AI for precision medicine and large‐scale cohorts

VIEW, Volume 7, Issue 4, August 2026.
Large‐scale cohorts and multimodal biomedical data have enabled powerful predictive models for clinical risk stratification, but prediction alone cannot guide effective interventions. This review introduces causal artificial intelligence as a design‐first framework that integrates target trial emulation, causal discovery, and robust effect estimation ...
Linlin Cao, Yudian Xu, Yifan Chen, Honghao Huang, Wei Xu, Jun Pu   +5 more
wiley   +1 more source

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki, Päivi Hirvensalo, Aleksi Tornio, Anne M. Filppula   +3 more
wiley   +1 more source

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

Infection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N, Yu X, Li L, Yang P, Dong R, Huang Y, Ling X, Shentu Q, Yu W, Jiang S   +9 more
doaj  

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016 ...
Belaynew W. Taye, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex J. Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Y. Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Wade, Wendy Cheng, Stuart K. Roberts, Paul J. Clark   +17 more
wiley   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
Anuradha Ramamoorthy, Alana Chen, Edwin Chiu Yuen Chow, Daphne Guinn, Anjali Iyer, Sonia Pahwa, Yunzhao Ren, Chinmay Shukla, Suresh Doddapaneni, Zhixia Yan Danielsen   +9 more
wiley   +1 more source

Physiologically‐based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co‐administered with ritonavir

CPT: Pharmacometrics & Systems Pharmacology
GLS4 is a first‐in‐class hepatitis B virus (HBV) capsid assembly modulator (class I) that is co‐administered with ritonavir to maintain the anticipated concentration required for the effective antiviral activity of GLS4.
Zexu Sun, Nan Zhao, Ran Xie, Bo Jia, Junyu Xu, Lin Luo, Yulei Zhuang, Yuyu Peng, Xinchang Liu, Yingjun Zhang, Xia Zhao, Zhaoqian Liu, Yimin Cui   +12 more
doaj   +1 more source